Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results

Theravance Biopharma (NASDAQ:TBPHGet Rating) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.06), Fidelity Earnings reports. During the same quarter last year, the company posted ($0.80) EPS.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH traded down $0.74 during mid-day trading on Friday, hitting $8.74. The stock had a trading volume of 1,175,107 shares, compared to its average volume of 1,027,146. Theravance Biopharma has a 1 year low of $6.10 and a 1 year high of $14.28. The business has a 50 day moving average price of $8.99 and a two-hundred day moving average price of $9.30. The firm has a market cap of $663.38 million, a P/E ratio of -4.26 and a beta of 0.69.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Theravance Biopharma by 10.3% in the first quarter. Vanguard Group Inc. now owns 6,947,947 shares of the biopharmaceutical company’s stock worth $66,421,000 after buying an additional 648,124 shares during the period. State Street Corp increased its stake in shares of Theravance Biopharma by 13.3% in the first quarter. State Street Corp now owns 1,541,533 shares of the biopharmaceutical company’s stock worth $14,737,000 after buying an additional 181,331 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Theravance Biopharma by 184.0% in the first quarter. Goldman Sachs Group Inc. now owns 976,373 shares of the biopharmaceutical company’s stock worth $9,335,000 after buying an additional 632,582 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Theravance Biopharma by 3.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 402,640 shares of the biopharmaceutical company’s stock worth $3,850,000 after buying an additional 12,095 shares during the period. Finally, PDT Partners LLC increased its stake in shares of Theravance Biopharma by 73.0% in the first quarter. PDT Partners LLC now owns 192,701 shares of the biopharmaceutical company’s stock worth $1,842,000 after buying an additional 81,322 shares during the period. 78.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TBPH has been the topic of several research reports. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Theravance Biopharma in a research note on Thursday, July 14th. SVB Leerink initiated coverage on shares of Theravance Biopharma in a research note on Monday, May 23rd. They set an “outperform” rating and a $12.00 price target on the stock. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $11.75.

Theravance Biopharma Company Profile

(Get Rating)

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

Recommended Stories

Earnings History for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.